Equities
Health CareMedical Equipment and Services
  • Price (USD)78.19
  • Today's Change-0.24 / -0.31%
  • Shares traded1.48m
  • 1 Year change+0.73%
  • Beta0.8816
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Henry Schein, Inc. is a solutions company for healthcare professionals. Its segments consist of Global Distribution and Value-Added services, Global Specialty Services, and Global Technology. Global Distribution and Value-Added Services include the distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting and other services. This segment also markets and sells under its own brand, a portfolio of consumable merchandise. The Global Specialty Products includes the manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other healthcare-related products and services. Global Technology includes the development and distribution of practice management software, e-services, and other products.

  • Revenue in USD (TTM)12.94bn
  • Net income in USD391.00m
  • Incorporated1992
  • Employees25.00k
  • Location
    Henry Schein Inc135 Duryea RdMELVILLE 11747United StatesUSA
  • Phone+1 (302) 636-5400
  • Fax+1 (302) 636-5454
  • Websitehttps://www.henryschein.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bruker Corp3.44bn-22.50m5.55bn11.40k--2.2427.861.61-0.1487-0.148722.6116.280.57051.675.71---0.12125.07-0.1556.7646.7049.41-0.21247.560.87397.790.426813.132.0811.57-119.89--4.344.56
Caris Life Sciences Inc-100.00bn-100.00bn5.82bn----12.16----------1.70------------------------9.36--0.4404--34.67--18.22------
Avantor Inc6.55bn-530.20m6.27bn13.50k--1.13--0.9577-0.7775-0.77759.628.160.54815.706.21485,348.20-4.442.78-5.173.1832.6533.77-8.095.001.183.610.41490.00-3.410.4913-174.52--15.90--
Glaukos Corp469.82m-87.61m6.29bn995.00--8.16--13.38-1.55-1.558.2813.410.48791.766.06472,180.90-9.10-11.24-9.92-12.0476.8773.54-18.65-36.684.47--0.0817--21.8510.10-8.70--5.93--
Bio Rad Laboratories Inc2.56bn-675.90m6.92bn7.70k--1.03--2.71-24.30-24.3092.91249.770.2521.535.52332,139.60-6.663.00-7.013.1552.4255.37-26.4314.513.940.24760.15150.00-3.922.11-189.37--13.91--
Masimo Corp1.72bn-203.80m6.99bn3.60k--8.53--4.08-3.83-10.6131.7015.250.69931.705.09476,416.70-8.313.29-10.463.9954.9653.94-11.884.561.925.880.40840.002.2617.43-474.11---6.75--
Repligen Corp707.89m1.74m7.68bn1.78k5,298.643.6992.4910.850.02580.025812.5537.010.2462.005.09398,138.300.06043.280.0633.7051.5954.240.245512.377.14--0.20520.000.328518.61-171.68--5.25--
Henry Schein Inc12.94bn391.00m9.20bn25.00k24.702.7613.040.71153.173.17104.7328.351.194.867.60517,520.003.705.436.369.1931.1930.233.103.980.78856.590.38720.002.714.88-6.25-11.0619.66--
Baxter International Inc11.02bn-355.00m10.18bn38.00k--1.4016.080.9237-0.6925-0.665421.4614.090.46183.146.08290,078.90-1.48-0.8441-1.87-1.0335.0538.63-3.20-2.031.183.420.5684--2.66-1.31-293.68---8.521.60
Revvity Inc2.86bn239.88m10.89bn11.00k46.361.5016.873.812.072.0824.4963.950.23263.464.15--1.953.232.133.5854.7758.488.4013.581.405.230.30758.523.67-5.47-15.26-19.91-1.050.00
Globus Medical Inc2.77bn423.78m11.79bn5.30k28.472.7016.844.263.093.0920.0932.680.54411.294.59522,604.508.324.709.535.1865.3466.4015.309.732.4715.960.00020.0060.6226.25-16.19-7.8810.29--
Solventum Corp8.40bn1.52bn13.10bn22.00k8.692.636.411.568.698.6948.0128.750.58513.857.91381,909.1010.61--13.32--54.18--18.13--1.141.760.5075--0.6954---64.41------
Penumbra Inc1.33bn164.03m13.31bn4.50k81.879.7873.379.984.144.1433.6334.700.82761.077.42296,399.6010.181.4211.311.5866.8063.2112.301.964.18--0.01710.0012.8616.89-84.59-21.98-0.853--
Align Technology Inc4.03bn410.35m13.40bn20.95k33.013.3132.683.325.665.6655.5856.430.64835.333.85--6.598.119.6711.9768.2570.4010.1712.311.24------0.89910.30-2.61-25.40----
Guardant Health Inc902.57m-398.79m13.51bn2.00k------14.97-3.21-3.217.27-2.840.64114.028.85451,510.30-28.33-24.20-33.49-26.8363.7663.23-44.18-91.243.12-10.701.47--31.0428.088.98--10.58--
Data as of Feb 13 2026. Currency figures normalised to Henry Schein Inc's reporting currency: US Dollar USD

Institutional shareholders

41.22%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 202510.70m9.09%
Artisan Partners LPas of 30 Sep 20256.83m5.80%
BlackRock Fund Advisorsas of 31 Dec 20255.33m4.53%
JPMorgan Investment Management, Inc.as of 31 Dec 20254.56m3.87%
SSgA Funds Management, Inc.as of 31 Dec 20254.40m3.74%
Palestra Capital Management LLCas of 30 Sep 20254.33m3.68%
American Century Investment Management, Inc.as of 31 Dec 20253.67m3.11%
Fidelity Management & Research Co. LLCas of 30 Sep 20253.04m2.58%
Invesco Capital Management LLCas of 30 Sep 20252.93m2.49%
Geode Capital Management LLCas of 31 Dec 20252.73m2.32%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.